Pure Biologics

Pure Biologics ROE

The Return on Equity (ROE) of Pure Biologics (PUR.WA) as of Oct 8, 2026 is 69.41 %. In the previous year, Return on Equity (ROE) was 148.18 % — a change of -53.15% (lower).

ROE

69.41 %

YoY

-53.15%

Last updated:

In 2025, Pure Biologics's return on equity (ROE) was 69.41 %, a -53.15% increase from the 148.18 % ROE in the previous year.

The Pure Biologics ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-31.04 PLN
Jan 1, 2019
-65.22 PLN
Jan 1, 2020
419.29 PLN
Jan 1, 2021
-33.10 PLN
Jan 1, 2022
-144.13 PLN
Jan 1, 2023
-1,885.58 PLN
Jan 1, 2024
148.18 PLN
Jan 1, 2025
69.41 PLN
The Pure Biologics ROE history
YEARROEYoY
69.41 %-53.15%
148.18 %-107.86%
-1,885.58 %+1,208.22%
-144.13 %+335.41%
-33.10 %-107.89%
419.29 %-742.88%
-65.22 %+110.13%
-31.04 %-84.22%
-196.75 %+41.65%
-138.89 %—
Access this data via the Eulerpool API
Get Free API Key

Pure Biologics Stock analysis

What does Pure Biologics do? Pure Biologics is one of the most popular companies on Eulerpool.

ROE Details

Decoding Pure Biologics's Return on Equity (ROE)

Pure Biologics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Pure Biologics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Pure Biologics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Pure Biologics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Pure Biologics stock

Return on Equity (ROE) of Pure Biologics is 69.41 % in 2025.

Return on Equity (ROE) of Pure Biologics changed from 148.18 % to 69.41 %, representing a -53.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Pure Biologics since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Pure Biologics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Pure Biologics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Pure Biologics